Enliven Therapeutics (NASDAQ:ELVN) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research report report published on Thursday morning, Marketbeat reports. The firm issued an overweight rating and a $75.00 price target on the stock.

Other analysts have also issued research reports about the company. HC Wainwright increased their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Stifel Nicolaus upped their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. JonesTrading increased their price objective on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, William Blair assumed coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating for the company. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $74.44.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $46.97 on Thursday. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The firm’s 50 day simple moving average is $55.23 and its 200-day simple moving average is $47.25. The company has a market cap of $3.44 billion, a P/E ratio of -28.13 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts expect that Enliven Therapeutics will post -1.75 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $50.35, for a total value of $303,006.30. Following the completion of the sale, the chief financial officer directly owned 38,000 shares in the company, valued at $1,913,300. The trade was a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares of the company’s stock, valued at $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 186,849 shares of company stock valued at $11,038,275. 3.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. First Light Asset Management LLC boosted its holdings in Enliven Therapeutics by 574.1% in the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after purchasing an additional 1,158,883 shares in the last quarter. Tidal Investments LLC raised its holdings in Enliven Therapeutics by 27.7% during the second quarter. Tidal Investments LLC now owns 60,694 shares of the company’s stock valued at $3,080,000 after buying an additional 13,179 shares in the last quarter. WINTON GROUP Ltd bought a new position in Enliven Therapeutics during the second quarter valued at about $228,000. Engineers Gate Manager LP acquired a new stake in shares of Enliven Therapeutics in the second quarter worth about $1,479,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Enliven Therapeutics in the second quarter worth about $259,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.